Dorzagliatin in drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial

Zhu, DL; Li, XY; Ma, JH; Zeng, JE; Gan, SL; Dong, XL; Yang, J; Lin, XH; Cai, HQ; Song, WH; Li, XF; Zhang, KQ; Zhang, Q; Lu, YB; Bu, RF; Shao, HG; Wang, GX; Yuan, GY; Ran, XW; Liao, L; Zhao, WN; Li, P; Sun, L; Shi, LX; Jiang, ZS; Xue, YM; Jiang, HW; Li, QN; Li, ZB; Fu, MX; Liang, ZR; Guo, L; Liu, M; Xu, C; Li, WH; Yu, XF; Qin, GJ; Yang, Z; Su, BL; Zeng, LY; Geng, HF; Shi, YQ; Zhao, Y; Zhang, Y; Yang, WY; Chen, L

Zhu, DL (通讯作者)，Nanjing Univ, Affiliated Drum Tower Hosp, Sch Med, Nanjing, Peoples R China.;Chen, L (通讯作者)，Hua Med, Shanghai, Peoples R China.;Yang, WY (通讯作者)，China Japan Friendship Hosp, Beijing, Peoples R China.

NATURE MEDICINE, 2022; 28 (5): 965

Abstract

Improving glucose sensitivity remains an unmet medical need in treating type 2 diabetes (T2D). Dorzagliatin is a dual-acting, orally bioavailable gluc......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索